Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03926260

Early Assessment of Response to Treatment of Metastatic LUng Tumors Based on CIrculating Tumor DNA — ELUCID  

Metastatic Non-small Cell Lung Cancer Clinical Trial

Official title:
Non-controlled Prospective Pilot Study Assessing Prognostic Performance of Circulating Tumour DNA Kinetic Analysis for Monitoring Response to Treatment of Metastatic Non-small Cell Lung Cancers

Clinical Trial Summary

In patients with locally advanced or metastatic tumors, first-line therapeutic management is based on the use of targeted therapies (EGFR, BRAF ALK and ROS1 inhibitors), immunotherapies (anti-PD1/ anti-PDL1-antibodies or chemotherapy. Despite patient selection based on histo-pathological and molecular criteria, not all patients respond to treatment. There are currently no markers to definitively guarantee a patient's response. An alternative is to identify early patient response to treatment. The investigator hypothesize that change in circulating tumor DNA concentration (ctDNA) allow to early identify patients' therapeutic response (and non-response) of patients, regardless of the type of treatment used in the first line setting.

Clinical Trial Description

The primary objective is to determine whether early evolution (between baseline and week 3) of circulating tumor DNA concentration predicts the radiological response to first-line treatment of advanced or metastatic NSCLC patients, regardless of treatment ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03926260
Study type Interventional
Source Centre Hospitalier Departemental Vendee
Contact
Status Completed
Phase N/A
Start date June 27, 2019
Completion date May 23, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT02857270 - A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Phase 1
Not yet recruiting NCT05985330 - Pilot Study of the Contribution of Fractional Exhaled Nitric Oxide as a Prognostic Marker of Response to Anti-PD-L1 Immunotherapy in Non-small Cell Lung Cancer
Recruiting NCT05013450 - Dupilumab_Metastatic NSCLC Phase 1/Phase 2
Recruiting NCT05984277 - A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. Phase 3
Completed NCT03215810 - Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer Phase 1
Completed NCT05675683 - Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib
Active, not recruiting NCT02411448 - A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) Phase 3
Recruiting NCT04410796 - Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers Phase 2
Recruiting NCT03300115 - Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC Phase 2
Recruiting NCT05635708 - A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer Phase 2
Terminated NCT03265080 - A Study of ADXS-NEO Expressing Personalized Tumor Antigens Phase 1
Active, not recruiting NCT05226598 - Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) Phase 3
Withdrawn NCT02639234 - Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer Phase 2
Recruiting NCT05364073 - Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations Phase 1
Active, not recruiting NCT03976375 - Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008) Phase 3
Recruiting NCT05546905 - A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS)
Withdrawn NCT01936961 - Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors N/A
Recruiting NCT06212752 - A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension Phase 3
Recruiting NCT05607550 - Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) Phase 3
Recruiting NCT03976856 - Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib Phase 1